

CIF A-18.758.300
Avda. de la Innovación, n 1
Edificio BIC (Ofic. 211)
P. T. de Ciencias de la Salud
18100 Armilla (Granada)
Tel: 958 750 598

Mercado Alternativo Bursátil
Plaza de la Lealtad, 1
28014 Madrid

In Granada, 02 December 2014

RELEVANT FACT OF NEURON BIO

In compliance with the provisions of the MAB circular 9/2010 on information to be provided by the companies in expansion integrated in the MAB the company, Neuron Bio, S.A. (hereinafter "NEURON BIO" or the "Company"), hereby informs that on 28 November 2014 the company has registered at the Spanish Patents and Trademarks Office (OEPM) a new patent application.

The patent application protects a method for the diagnosis of for people affected with Smith-Lemli-Opitz syndrome (SLOS) determining levels of different blood markers related to the disease. SLOS is a rare, inherited disease associated to an inborn error of the biosynthesis from cholesterol caused by a deficiency of the 7-dehydrocholesterol reductase.

This is the first patent application of the Company in the diagnosis area of the central nervous systems diseases. It is the result of the work carried out in recent years by Neuron Bio in this field.

The invention provides a reliable, reproducible and non-invasive method for the diagnosis of affected people and for the evaluation of disease progression. Moreover, the determination of these biomarkers may allow evaluating the effect of treatments for this syndrome and may suggest new therapeutic targets in the search of the treatment of this pediatric pathology.

We remain at your disposal for any clarification you consider appropriate.

Kind regards,

Fernando Valdivieso Amate
Chairman of the Board of Directors